As 2024 draws to a close, we’ve put together a snapshot of some of our key research stories and events that we hosted over the year.
A massive THANK YOU to all our Read more
New research has found a change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts from treatment.Read more
Research from the University of Cambridge’s Cardiovascular Epidemiology Unit and funded by NIHR Cambridge BRC are listed in the top five most-cited papers in the European Heart Journal over 2023.Read more
Researchers in this theme will be looking at finding better ways to predict and prevent stillbirth and infant mortality. Read more
This theme will investigate heart and lung diseases and how using artificial intelligence (AI) could identify patterns in data to improve diagnosis. Read more
Researchers will explore the use of population data to improve early detection health conditions to change outcomes. Read more
Developed in line with the Life Sciences Vision 2021, this theme aims to expedite patient access to new treatments & technologies.Read more
Working with our partners, including patients, this theme aims to drive adoption of genomics into everyday healthcare.Read more
This theme will explore ways to develop personalised treatments for patients with immune disorders and improve outcomes of organ transplants. Read more
Cambridge has a strong track record in microbiology and infectious diseases research, from basic science to clinical studies. Read more
Researchers will study the links between physical and mental health conditions, as well as improve therapies and treatments. Read more
This theme aims to develop treatments for all dementias, as well as creating new diagnostic tools to identify the disease earlier.Read more
Neurological disorders affect 1 in 6 in the UK and are complex and highly variable, with limited treatment opportunities. Read more
Our research aims are to improve the lives and health of people with obesity, diabetes and related metabolic and endocrine diseases. Read more